ArticleCancer immunology, immunotherapy : CII2026
The increased co-expression of SLC7A11 and PD-L1 was associated with poor prognosis in extranodal natural killer T-cell lymphoma patients.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Extranodal natural killer/T‑cell lymphoma (ENKTL) is a highly aggressive type of mature T and NK cell lymphoma that faces treatment challenges. Although immune checkpoint inhibitors (ICIs) have shown clinical activity in ENKTL, primary resistance and limited durable responses remain major obstacles. Our previous study demonstrated that the natural diterpenoid compound kayadiol exerted antitumor activity via p53/SLC7A11‑mediated ferroptosis in ENKTL cells. Cystine, through the solute carrier family 7 member 11 (SLC7A11)-a cystine/glutamate antiporter-serves as the primary regulator of cystine uptake for glutathione biosynthesis. To evaluate the expression patterns of SLC7A11 in ENKTL, we conducted immunohistochemistry (IHC) analyses on formalin‑fixed paraffin‑embedded (FFPE) specimens obtained from 42 newly diagnosed ENKTL patients. The results indicated that high expression of SLC7A11 was associated with decreased overall survival (OS) and progression‑free survival (PFS). Furthermore, the simultaneous detection of PD‑L1 expression revealed a correlation between the expressions of SLC7A11 and PD‑L1, with their mutual high expression also linked to an unfavorable prognosis. To further assess the co‑expression pattern of SLC7A11 and PD‑L1 in tumor cells, we performed fluorescent multiplex immunohistochemistry (mIHC). Notably, both SLC7A11 and PD‑L1 were confirmed to be predominantly localized to CD56
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.